Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dengue Fever Vaccine (Multi-epitope Peptide) is an epitope-based vaccine candidate developed by Asia Biotech for the prevention of Dengue fever. The vaccine is designed to target all four serotypes of the dengue virus (DENV-1, DENV-2, DENV-3, and DENV-4) by presenting conserved peptide epitopes to the host immune system. This multi-epitope approach, developed using Asia Biotech's Epitope Platform, aims to induce broad and cross-reactive protective immunity against the virus. As of the latest pipeline reports, the candidate is in the preclinical stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dengue Fever Vaccine (Multi-epitope Peptide).